Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695939 | 0.91 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| Hydrochloric Acid SCHEMBL8053510 | 0.90 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL316883 | 0.86 | CA1 (0.66) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL31174375 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL3730231 | 0.84 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1MAPK1KMT2ASLC6A2 | |
| SCHEMBL4073528 | 0.84 | TPSAB1 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL1171418 | 0.84 | LMNA (0.56) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL8404075 | 0.83 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL6518216 | 0.83 | PPID (0.59) | ALDH1A1L3MBTL1MAPK1CA1CA2 | |
| SCHEMBL26331487 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | ALDH1A1 1757/4885L3MBTL1 3542/4885MAPK1 3777/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | ALDH1A1 1757/4885L3MBTL1 3542/4885MAPK1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.